BUZZ-Formycon up after it unveils development of biosimilar candidate for Dupixent
Reuters
Yesterday
BUZZ-Formycon up after it unveils development of biosimilar candidate for Dupixent
** Shares in Formycon FYB.DE rise around 8% after it said it was developing its FYB208 drug as a biosimilar candidate for the immunological drug Dupixent
** The anti-inflammatory drug Dupixent is made by the U.S. drugmaker Regeneron Pharmaceuticals REGN.O in partnership with SanofiSASY.PA
** Formicon says preclinical milestone technical proof of similarity (TPoS) demonstrates high analytical comparability of FYB208 to reference drug
** The stock is at the top of German small-cap index .SDAXI
(Reporting by Amir Orusov)
((Amir.orusov@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.